Mg-ZIF nanozyme regulates the switch between osteogenic and lipogenic differentiation in BMSCs via lipid metabolism

Lipids Health Dis. 2024 Mar 25;23(1):88. doi: 10.1186/s12944-024-02083-3.

Abstract

The accumulation of reactive oxygen species (ROS) within the bone marrow microenvironment leads to diminished osteogenic differentiation and heightened lipogenic differentiation of mesenchymal stem cells residing in the bone marrow, ultimately playing a role in the development of osteoporosis (OP). Mitigating ROS levels is a promising approach to counteracting OP. In this study, a nanozyme composed of magnesium-based zeolitic imidazolate frameworks (Mg-ZIF) was engineered to effectively scavenge ROS and alleviate OP. The results of this study indicate that Mg-ZIF exhibits significant potential in scavenging ROS and effectively promoting osteogenic differentiation of bone mesenchymal stem cells (BMSCs). Additionally, Mg-ZIF was found to inhibit the differentiation of BMSCs into adipose cells. In vivo experiments further confirmed the ability of Mg-ZIF to mitigate OP by reducing ROS levels. Mechanistically, Mg-ZIF enhances the differentiation of BMSCs into osteoblasts by upregulating lipid metabolic pathways through ROS scavenging. The results indicate that Mg-ZIF has potential as an effective therapeutic approach for the treatment of osteoporosis.

Keywords: BMSCs; Lipid metabolism; Mg-ZIF nanozyme; Osteogenic differentiation; Osteoporosis; ROS.

MeSH terms

  • Bone Marrow Cells
  • Cell Differentiation
  • Cells, Cultured
  • Humans
  • Lipid Metabolism / genetics
  • Magnesium
  • Mesenchymal Stem Cells*
  • Osteogenesis / genetics
  • Osteoporosis* / drug therapy
  • Osteoporosis* / genetics
  • Osteoporosis* / metabolism
  • Reactive Oxygen Species / metabolism

Substances

  • Magnesium
  • Reactive Oxygen Species